Senior Formulation Development Scientist
(This position is handled by our Nordic partner, Borka Consulting. See contact data for recruiter André Borka in Borka Consulting in the job advertisement)
Senior Formulation Development Scientist
✔biologics ✔improved product formulation ✔formulation expertise
The CMC team in Vaccibody is expanding their team and looking for a highly motivated and enthusiastic Senior Formulation Development Scientist to join their adventure in the further development of the Vaccibody pDNA products with particular focus on formulation development and regulatory perspectives of the vaccines. The work will be performed in close collaboration with the entire CMC team in addition to external partners.
You will design and plan the experiments, prepare protocols and perform some of the experiments in the lab, with subsequent documentation. You will also be the go-to person for Vaccibody and external collaborators with respect to Formulation Development
Keeping updated on relevant literature
Planning and performing lab experiments in accordance with Vaccibody strategy
Work closely with the entire CMC and Research teams in addition to external partners to align the experiments performed in all areas
Use the data generated to develop improved Vaccibody vaccines
Act as the formulation specialist in Vaccibody and support all projects
Education and experience requirements:
MSc or PhD in pharmaceutical sciences, chemistry, biochemistry or similar
Experience in working with pDNA and/or other biologics
Track record in pharmaceutical formulation development
5-10 years’ experience from big pharma or biotech
Skilled user of IT systems
Proficiency in English both verbal and in writing
Have strong interpersonal skills and possess the ability to communicate with other staff in a fast-paced setting
Take responsibility and be able to work independently
Flexibility and enjoy handling multiple tasks at the same time
Be a team player with a “we” mentality
Have an analytical, structured, and innovative mindset
Forskningsparken, Oslo, Norway
This recruitment is carried out in collaboration with the recruitment company Borka Consulting AS. If you have any questions regarding Vaccibody or the position, feel free to contact our recruitment advisor in Borka Consulting; André Borka at +47 908 31 871 or Cecilie Fraas Borka at +47 928 55 352.
Please send your application (both motivational letter and CV in PDF format) to email@example.com.
Norwegian applicants may apply in Norwegian. In the application letter, please highlight which of the above-mentioned “Education, experience and other qualifications” you fulfill. All inquiries are treated confidentially, also towards Vaccibody in the initial phase if desired.
We look forward to receiving your application!
Who are we looking for?
When hiring new employees, we look for the individuals who we think would be a good fit with our collaborative and inclusive company culture. You enjoy working together with other people in cross-functional team structures. Moreover, you appreciate working in an international environment.
Why join our Vaccibody team?
At Vaccibody, we offer a fun and dynamic international working environment. The people are at the heart of our organization, which is why we always keep striving to offer a workplace where we cheer each other on and find motivation. Your skills and competencies are unique and to ensure continued development our aspiration is to provide you with good opportunities for personal growth. We care about each other.
Our company was founded in 2007 and has since then, become one of the world’s most exciting Biotech companies, rapidly growing. Today we are counting more than 60 amazing employees within medical and development teams, manufacturing, bioinformatics, and research teams. We use the Vaccibody technology to generate therapeutics with best-in-class potential to treat cancers with a high unmet medical need. Furthermore, we also focus our research on infectious diseases and immune tolerance. We closely collaborate with Roche and Nektar Therapeutics. And we are proud to have entered into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccines.